Main Article Content
scientometric, bibliometric, hidradenitis suppurativa, acne inversa
Background: Hidradenitis Suppurativa (HS) is a chronic condition that requires prompt diagnosis and treatment. To date, no bibliometric analysis on HS exists. Analyzing the top 100 citations is important to understand the characteristics of the most influential studies in the HS research landscape, and to guide future research.
Objective: To analyze the top 100 most cited articles on HS using bibliometric analysis.
Methods: Searches within Scopus and Web of Science using "Hidradenitis Suppurativa" and "Acne Inversa" were conducted on May 14th, 2020. After excluding non-original articles, data for the top 100 articles were analyzed using R-studio and Bibliometrix. Five independent reviewers identified study topic and design.
Results: The top 100 most cited articles on HS were published between 1982 and 2017 with an average of 128.3 citations. The top research topic and design were treatment (40 articles) and randomized controlled trials (9), respectively. 2011 had the highest number of publications (9), and the 2012 article by Gregor B. E. Jemec had the highest citations (439). These articles were from 14 different countries with the United States and Denmark as top countries. 27 journals published these articles with the British Journal of Dermatology (BJD) as the top journal. Denmark had the greatest outside country collaborations.
Conclusions: The results of our study showed that HS research is steadily growing with greatest support from the BJD. There is a focus on treatments in HS research with the United States and European countries leading the way. However, greater worldwide research of HS is needed.
2. Szepietowski JC, Matusiak L. Hidradenitis Suppurativa: The Disease Which Stimulates Researchers and Clinicians. Dermatology. 2020;236(1):5-7.
3. Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81(1):76-90.
4. Widlund H. Notch Signaling. Cell Signaling Technology. Published 2012. Accessed.
5. Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. Journal of the American Academy of Dermatology. 2019;81(1):76-90.
6. Hendricks AJ, Hsiao JL, Lowes MA, Shi VY. A Comparison of International Management Guidelines for Hidradenitis Suppurativa. Dermatology. 2019:1-16.
7. Thompson DF, Walker CK. A descriptive and historical review of bibliometrics with applications to medical sciences. Pharmacotherapy. 2015;35(6):551-559.
8. Glänzel W, Moed HF. Journal impact measures in bibliometric research. Scientometrics. 2002;53(2):171-193.
9. Wu JJ, Choi YM, Marczynski W. The 100 most cited psoriasis articles in clinical dermatologic journals, 1970 to 2012. J Clin Aesthet Dermatol. 2014;7(10):10-19.
10. Berlinberg A, Bilal J, Riaz IB, Kurtzman DJB. The 100 top-cited publications in psoriatic arthritis: a bibliometric analysis. Int J Dermatol. 2019;58(9):1023-1034.
11. Wang Y, Zhang H, Fang R, Tang K, Sun Q. The top 100 most cited articles in rosacea: a bibliometric analysis. J Eur Acad Dermatol Venereol. 2020.
12. Joyce CW, Sugrue CM, Joyce KM, Kelly JL, Regan PJ. 100 citation classics in the melanoma literature: a bibliometric analysis. Dermatol Surg. 2014;40(12):1284-1298.
13. Venable GT, Shepherd BA, Loftis CM, et al. Bradford's law: identification of the core journals for neurosurgery and its subspecialties. J Neurosurg. 2016;124(2):569-579.
14. Aria M, Cuccurullo C. bibliometrix: An R-tool for comprehensive science mapping analysis. Journal of Informetrics. 2017;11(4):959-975.
15. Egeberg A, Gislason GH, Hansen PR. Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa. JAMA Dermatology. 2016.
16. Jemec GBE. Hidradenitis suppurativa. New England Journal of Medicine. 2012.
17. Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045-1058.
18. Parati G. Antihypertensive therapy in 2014: Linking pathophysiology to antihypertensive treatment. Nat Rev Cardiol. 2015;12(2):77-79.
19. Howes OD, McGuire PK, Kapur S. Understanding pathophysiology is crucial in linking clinical staging to targeted therapeutics. World Psychiatry. 2008;7(3):162-163.
20. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled crossover trial. Journal of the American Academy of Dermatology. 2010.
21. Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. New England Journal of Medicine. 2016.
22. Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59(4):596-601.
23. Garfield E. 100 citation classics from the Journal of the American Medical Association. JAMA. 1987;257(1):52-59.
24. Jemec GB, Kimball AB. Hidradenitis suppurativa: Epidemiology and scope of the problem. J Am Acad Dermatol. 2015;73(5 Suppl 1):S4-7.
25. Phan K, Charlton O, Smith SD. Global prevalence of hidradenitis suppurativa and geographical variation—systematic review and meta-analysis. Biomedical Dermatology. 2020;4(1):2.
26. Alavi A, Anooshirvani N, Kim WB, Coutts P, Sibbald RG. Quality-of-life impairment in patients with hidradenitis suppurativa: a Canadian study. Am J Clin Dermatol. 2015;16(1):61-65.
27. Loonen MP, Hage JJ, Kon M. Plastic Surgery Classics: characteristics of 50 top-cited articles in four Plastic Surgery Journals since 1946. Plast Reconstr Surg. 2008;121(5):320e-327e.